MedTrace Logo

Rezvilutamide Plus Abiraterone for Metastatic Hormone-sensitive Prostate Cancer

NCT06134271 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2023-11-18

No results posted yet for this study

Summary

This multicenter, prospective, cohort study enrolled patients with metastatic hormone-sensitive prostate cancer who had been treated with other novel endocrine or systemic regimens (excluding patients treated with pre-order chemotherapy alone or bicalutamide); To observe the efficacy and safety of rezvilutamide alone or in combination with abiraterone in hormone-sensitive prostate cancer patients with PSA progression following prior sequence therapy.

Conditions

Interventions

DRUG

Rezvilutamide

Rezvilutamide 240mg qd

DRUG

Rezvilutamide plus abiraterone

Rezvilutamide 240mg qd plus abiraterone 1000mg + prednisone 5 mg qd

DRUG

Continue previous treatment

Continue using the previous treatment regimen for treatment.

Sponsors & Collaborators

  • Jianbin Bi

    lead OTHER

Principal Investigators

  • Jianbin Bi · First Hospital of China Medical University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-15
Primary Completion
2025-04-30
Completion
2026-04-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06134271 on ClinicalTrials.gov